Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab with Chemotherapy in EGFR Wild-type NSCLC
NCT01623102Phase 2Unknown
- Sponsor
- Sichuan Cancer Hospital
- Start
- Feb 2013
- Primary completion
- Aug 2014
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bevacizumab in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC) (2 arms), sponsored by Sichuan Cancer Hospital. Primary endpoint: Disease-free time to progression at 6 week. Status: unknown.
02
Drugs
bevacizumab
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT01623102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01623102.